Patterns of Craving and Pharmacokinetics in Long-Term Opiate Addicts in Methadone Maintenance Therapy

References

• Baselt R. C, Casarett L. J. Urinary excretion of methadone in man. Clin. Pharmacol Ther. 1972; 13: 64–70
   PubMed Web of Science ®Google Scholar
• Ball J. C., Ross A. The effectiveness of methadone maintenance treatment. Springer-Verlag, New York 1991
   Google Scholar
• Bell J., Seres V., Bowron P., Lewis J., Batey R. The use of serum methadone levels in patients receiving methadone maintenance. Clin. Pharmacol. Then 1988; 43: 623–629
   PubMed Web of Science ®Google Scholar
• Bell J., Bowron P., Lewis J., Batey R. Serum levels of methadone in maintenance clients who persist in illicit drug use. Br. J. Addict. 1990; 85: 1599–1602
   PubMedGoogle Scholar
• Bellward G. D., Warren P. M., Howard W., Axelson J. E., Abbott F. S. Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Clin. Pharmacol. Ther. 1977; 22: 92–99
   PubMed Web of Science ®Google Scholar
• Caplehorn J. R., Bell J., Kleinbaum D. G., Gebski V. J. Methadone dose and heroin use during maintenance treatment. Addiction 1993; 88: 119–124
   PubMed Web of Science ®Google Scholar
• Caplehorn J. R., Dalton M. S., Cluff M. C., Petrenas A. M. Retention in methadone maintenance and heroin addict's risk of death. Addiction 1994; 89: 203–209
   PubMed Web of Science ®Google Scholar
• Childress A. R., McLellan A. T., O'Brien C. P. Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. J. Subst. Abuse Treat. 1986; 3: 173–179
   PubMedGoogle Scholar
• Csikszentmihaly M., Larson R. Validity and reliability of the experience-sampling method. J. Nerv. Ment. Dis. 1987; 175: 526–536
   PubMedGoogle Scholar
• De Vos J. W., Geerlings P. J., van den Brink W., Ufkes J. G. R., vanWilgenburg H. Pharmacokinetics of methadone and its primary metabolite in twenty opiate addicts. Eur. J. Clin. Pharmacol 1995; 48: 361–366
   PubMed Web of Science ®Google Scholar
• De Vos J. W., van den Brink W. Opiate craving and presence of psychopathology. Eur. Addict. Res., Submitted
   Google Scholar
• De Vries M. W. Investigating mental disorders in their natural settings. J. Nerv. Mem. Disease 1987; 175: 509–513
   Google Scholar
• Dole V. P., Nyswander M. E. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193: 646–650
   PubMed Web of Science ®Google Scholar
• Dole V. P. Conversation with Vincent Dole. Addiction 1994; 89: 23–29
   PubMed Web of Science ®Google Scholar
• Goldstein A., Hansteen R. W., Horns W. H. Control of methadone dosage by patients. JAMA 1975; 234: 734–737
   PubMed Web of Science ®Google Scholar
• Handal P. J., Lander J. J. Methadone treatment: program evaluation and dose response relationships. Int. J. Addict. 1976; 11: 363–375
   PubMed Web of Science ®Google Scholar
• Hargreaves W. A. Methadone dosage and duration for maintenance treatment. Research on the treatment of narcotic addiction, J. R. Cooper, Washington, DC 1983, DHHS Publication no. (ADM) 97–1281
   Google Scholar
• Holmstrand J., Anggard E., Gunne L. M. Methadone maintenance: plasma levels and therapeutic outcome. Clin. Pharmacol. Then 1978; 23: 176–180
   Google Scholar
• Horns W. H., Rado M., Goldstein A. Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin. Pharmacol. Ther. 1975; 17: 636–649
   PubMed Web of Science ®Google Scholar
• Hubbard R. L., Marsden M. E., Fachas J. V., Harwood H. J., Cavanaugh E. R., Ginzburg H. M. Drug abuse treatment: a national study of effectiveness. University of North Carolina Press, Chapel Hill 1989
   Google Scholar
• Kaplan C. D. Drug craving and drug use in the daily life of heroin addicts. The experience of psy-chopathology: Investigating mental disorders in their natural settings, M W de Vries. Cambridge University Press, Cambridge 1992
   Google Scholar
• Kell M. J. Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J. Addict. Dis. 1994; 13: 5–26
   PubMedGoogle Scholar
• Kreek M. J., Bencsath F. A., Field F. H. Effects of liver disease on urinary excretion of methadone and metabolites in maintenance patients: quantitation by direct probe chemical ionization mass spectrometry. Biomed. Mass. Specirom. 1980; 7: 385–395
   PubMedGoogle Scholar
• Ling W., Rawson R. A., Compton M. A. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J. Psychoacl. Drugs 1994; 26: 119–128
   PubMed Web of Science ®Google Scholar
• Loimer N., Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend 1992; 30: 241–246
   PubMed Web of Science ®Google Scholar
• Maddux J. F., Esquivel M., Vogtsberger K. N., Desmond D. P. Methadone dose and urine morphine. J. Subsl. Abuse Treat. 1991; 8: 195–201
   PubMed Web of Science ®Google Scholar
• Maremmani I., Zolesi O., Agneci T., Castrogiovanni P. Methadone doses and psychopathological symptoms during methadone maintenance. J. Psychoact. Drugs 1993; 25: 253–256
   PubMed Web of Science ®Google Scholar
• Maremmani I., Nardini R., Zolesi O., Castrogiovanni P. Methadone dosages and therapeutic compliance during a methadone maintenance program. Drug Alcohol Depend 1994; 34: 163–166
   PubMed Web of Science ®Google Scholar
• Nilsson M. I., Widerlov E., Meresaar U., Anggard E. Effect of urinary pH on the disposition of methadone in man. Eur. J. Clin. Pharmacol. 1982; 22: 337–342
   PubMed Web of Science ®Google Scholar
• Norusis M. J. SPSS-PC plus base manual. SPSS, Chicago 1988
   Google Scholar
• Novick D. M., Kreek M. J., Fanizza A. M., Yancovitch S. R., Gelb A. M., Stenger R. J. Methadone disposition in patients with chronic liver disease. Clin. Pharmacol. Ther 1981; 30: 353–362
   PubMedGoogle Scholar
• Parrino M. W. Consensus Panel Chair. State methadone treatment guidelines. Rockville, MD 1993, Treatment Improvement Protocol (TIP) Series. DHHS Publication no. (SMA) 93–1991
   Google Scholar
• Powell J., Bradley B., Gray J. Classical conditioning and cognitive determinants of subjective craving for opiates: an investigation of their relative contributions. Brit. J. Addict. 1992; 87: 1133–1144
   PubMedGoogle Scholar
• Robinson T. E., Berridge K. C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews 1993; 18: 247–291
   PubMed Web of Science ®Google Scholar
• Roszell D. K., Calsyn D. A. Methadone dosage: patient characteristics and clinical correlates. Int. J. Addict. 1986; 21: 1233–1246
   PubMed Web of Science ®Google Scholar
• Simpson D. D., Sells S. B. Effectiveness of treatment for drug abuse: An overview of the DARP research program. Advances in Alcohol and Substance Abuse 1982; 2: 7–29
   Google Scholar
• Strain E. C, Stitzer M. L., Liebson I. A., Bigelow G. E. Dose-response effects of methadone in the treatment of opioid dependence. Ann. Intern. Med. 1993a; 119: 23–27
   PubMed Web of Science ®Google Scholar
• Strain E. C, Stitzer M. L., Liebson I. A., Bigelow G. E. Methadone dose and treatment outcome. Drug Alcohol Depend 1993b; 33: 105–117
   PubMed Web of Science ®Google Scholar
• Tennant F. S., Jr, Rawson R. A., Cohen A., Tarver A., Clabough D. Methadone plasma levels and persistent drug abuse in high dose maintenance patients. NIDA Res. Monogr. 1984; 49: 262–268
   PubMedGoogle Scholar
• Treece C., Nicholson B. DSM-III personality type and dose levels in methadone maintenance patients. J. Nerv. Ment. Dis. 1980; 168: 621–628
   PubMed Web of Science ®Google Scholar
• Whitehead C. C. Methadone pseudowithdrawal syndrome: paradigm for a psychopharmacological model of opiate addiction. Psychosom. Med. 1974; 36: 189–198
   PubMed Web of Science ®Google Scholar